156 related articles for article (PubMed ID: 19568235)
1. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V; Santoro A; Bennicelli E; Punt CJ; Citterio G; Timmer-Bonte JN; Caligaris Cappio F; Lambiase A; Bordignon C; van Herpen CM
Br J Cancer; 2009 Jul; 101(2):219-24. PubMed ID: 19568235
[TBL] [Abstract][Full Text] [Related]
2. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Gregorc V; Citterio G; Vitali G; Spreafico A; Scifo P; Borri A; Donadoni G; Rossoni G; Corti A; Caligaris-Cappio F; Del Maschio A; Esposito A; De Cobelli F; Dell'Acqua F; Troysi A; Bruzzi P; Lambiase A; Bordignon C
Eur J Cancer; 2010 Jan; 46(1):198-206. PubMed ID: 19900802
[TBL] [Abstract][Full Text] [Related]
3. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Gregorc V; De Braud FG; De Pas TM; Scalamogna R; Citterio G; Milani A; Boselli S; Catania C; Donadoni G; Rossoni G; Ghio D; Spitaleri G; Ammannati C; Colombi S; Caligaris-Cappio F; Lambiase A; Bordignon C
Clin Cancer Res; 2011 Apr; 17(7):1964-72. PubMed ID: 21307147
[TBL] [Abstract][Full Text] [Related]
5. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Ferreri AJM; Calimeri T; Conte GM; Cattaneo D; Fallanca F; Ponzoni M; Scarano E; Curnis F; Nonis A; Lopedote P; Citterio G; Politi LS; Foppoli M; Girlanda S; Sassone M; Perrone S; Cecchetti C; Ciceri F; Bordignon C; Corti A; Anzalone N
Blood; 2019 Jul; 134(3):252-262. PubMed ID: 31118164
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW; Fiedler W; Desar IM; van Asten JJ; Marréaud S; Lacombe D; Govaerts AS; Bogaerts J; Lasch P; Timmer-Bonte JN; Lambiase A; Bordignon C; Punt CJ; Heerschap A; van Herpen CM
Clin Cancer Res; 2010 Feb; 16(4):1315-23. PubMed ID: 20145168
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours.
Zucali PA; Simonelli M; De Vincenzo F; Lorenzi E; Perrino M; Bertossi M; Finotto R; Naimo S; Balzarini L; Bonifacio C; Timofeeva I; Rossoni G; Mazzola G; Lambiase A; Bordignon C; Santoro A
Br J Cancer; 2013 Jan; 108(1):58-63. PubMed ID: 23169299
[TBL] [Abstract][Full Text] [Related]
8. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Mammoliti S; Andretta V; Bennicelli E; Caprioni F; Comandini D; Fornarini G; Guglielmi A; Pessino A; Sciallero S; Sobrero AF; Mazzola G; Lambiase A; Bordignon C
Ann Oncol; 2011 Apr; 22(4):973-978. PubMed ID: 20855468
[TBL] [Abstract][Full Text] [Related]
9. NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Gregorc V; Cavina R; Novello S; Grossi F; Lazzari C; Capelletto E; Genova C; Salini G; Lambiase A; Santoro A
Oncologist; 2018 Oct; 23(10):1133-e112. PubMed ID: 30076277
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
Gregorc V; Zucali PA; Santoro A; Ceresoli GL; Citterio G; De Pas TM; Zilembo N; De Vincenzo F; Simonelli M; Rossoni G; Spreafico A; Grazia Viganò M; Fontana F; De Braud FG; Bajetta E; Caligaris-Cappio F; Bruzzi P; Lambiase A; Bordignon C
J Clin Oncol; 2010 May; 28(15):2604-11. PubMed ID: 20406925
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
Desar IM; van Herpen CM; van Asten JJ; Fiedler W; Marreaud S; Timmer-Bonte JN; ter Voert EG; Lambiase A; Bordignon C; Heerschap A; van Laarhoven HW
Eur J Radiol; 2011 Dec; 80(3):655-61. PubMed ID: 20863638
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.
Lorusso D; Scambia G; Amadio G; di Legge A; Pietragalla A; De Vincenzo R; Masciullo V; Di Stefano M; Mangili G; Citterio G; Mantori M; Lambiase A; Bordignon C
Br J Cancer; 2012 Jun; 107(1):37-42. PubMed ID: 22644293
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
Santoro A; Rimassa L; Sobrero AF; Citterio G; Sclafani F; Carnaghi C; Pessino A; Caprioni F; Andretta V; Tronconi MC; Finocchiaro G; Rossoni G; Zanoni A; Miggiano C; Rizzardi GP; Traversari C; Caligaris-Cappio F; Lambiase A; Bordignon C
Eur J Cancer; 2010 Oct; 46(15):2746-52. PubMed ID: 20708923
[TBL] [Abstract][Full Text] [Related]
14. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Santoro A; Pressiani T; Citterio G; Rossoni G; Donadoni G; Pozzi F; Rimassa L; Personeni N; Bozzarelli S; Rossoni G; Colombi S; De Braud FG; Caligaris-Cappio F; Lambiase A; Bordignon C
Br J Cancer; 2010 Sep; 103(6):837-44. PubMed ID: 20717115
[TBL] [Abstract][Full Text] [Related]
15. Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
Ferreri AJM; Calimeri T; Ponzoni M; Curnis F; Conte GM; Scarano E; Rrapaj E; De Lorenzo D; Cattaneo D; Fallanca F; Nonis A; Foppoli M; Lopedote P; Citterio G; Politi LS; Sassone M; Angelillo P; Guggiari E; Steffanoni S; Tarantino V; Ciceri F; Bordignon C; Anzalone N; Corti A
Blood Adv; 2020 Aug; 4(15):3648-3658. PubMed ID: 32766857
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.
Schliemann C; Hemmerle T; Berdel AF; Angenendt L; Kerkhoff A; Hering JP; Heindel W; Hartmann W; Wardelmann E; Chawla SP; de Braud F; Lenz G; Neri D; Kessler T; Berdel WE
Eur J Cancer; 2021 Jun; 150():143-154. PubMed ID: 33901793
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling.
Valentinis B; Porcellini S; Asperti C; Cota M; Zhou D; Di Matteo P; Garau G; Zucchelli C; Avanzi NR; Rizzardi GP; Degano M; Musco G; Traversari C
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31547231
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
Schelman WR; Morgan-Meadows S; Marnocha R; Lee F; Eickhoff J; Huang W; Pomplun M; Jiang Z; Alberti D; Kolesar JM; Ivy P; Wilding G; Traynor AM
Cancer Chemother Pharmacol; 2009 May; 63(6):1147-56. PubMed ID: 19082825
[TBL] [Abstract][Full Text] [Related]
19. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
[TBL] [Abstract][Full Text] [Related]
20. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
